News of Note—Vaccine exemption 'hot spots,' NIAID’s RSV vaccine study and more


Here is some other vaccine news of note for the week.

> Some regions in the 18 states that allow parents to opt their children out of school immunization requirements for nonmedical reasons could be vulnerable to vaccine-preventable diseases, a new study shows. The Washington Post article

> The National Institute of Allergy and Infectious Diseases (NIAID) has started a human study of an intranasal vaccine against respiratory syncytial virus (RSV). Release

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

> Combining a pre-erythrocytic malaria vaccine like GlaxoSmithKline’s Mosquirix with a transmission-blocking vaccine, which prevents mosquitoes from transferring the parasites, could boost protection to around 91%, a study in mice shows. Release

> Adel Mahmoud, M.D., Ph.D., who was president of Merck Vaccines from 1998 to 2006, died on June 11. He oversaw the creation of HPV vaccine Gardasil, rotavirus vaccine RotaTeq, shingles vaccine Zostavax, and measles, mumps, rubella and chicken pox combo shot ProQuad. The New York Times article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.